This database contains 350 studies, archived under the term: "therapeutic use"
Click here to filter this large number of results.
Donepezil treatment in Alzheimer’s disease patients with and without cerebrovascular lesions: a preliminary report
Na, Hae-Ri,
Kim, SangYun,
Choi, Seong Hye,
Yang, Dong-Won,
Bae, Hee-Joon,
Kim, Jung-Eun,
Park, Mee-Young,
Shim, Yong-Soo,
Kim, Byung-Kun,
Kwon, Jae-Cheol,
Yoo, Bong Goo,
Kim, Byeong-Chae,
Lee, Jung-Seok
Aim: Donepezil has not been evaluated in Korean patients with Alzheimer’s disease (AD) for up to 1 year. The objectives of this study were to evaluate the differential efficacy of donepezil in Korean AD patients with and without concomitant cerebrovascular lesions (CVL).; Methods: This study was a 48-week open-label trial of donepezil in patients with […]
SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study
Maher-Edwards, Gareth,
Dixon, Ruth,
Hunter, Jackie,
Gold, Michael,
Hopton, Gillian,
Jacobs, Gemma,
Hunter, Jo,
Williams, Pauline
Objective: To estimate the treatment effects of SB-742457 and donepezil in Alzheimer disease (AD) in a contemporary clinical trial.; Method: Randomized, controlled, parallel-group, exploratory study with a 4-week, single-blind, placebo run-in phase and 24-week, double-blind treatment phase. Primary endpoints were Clinician’s Interview-Based Impression of Change with caregiver input (CIBIC+) and the Alzheimer’s Disease Assessment Scale-cognitive […]
Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation
Lott, Ira T.,
Doran, Eric,
Nguyen, Vinh Q.,
Tournay, Anne,
Head, Elizabeth,
Gillen, Daniel L.
Individuals with Down syndrome over age 40 years are at risk for developing dementia of the Alzheimer type and have evidence for chronic oxidative stress. There is a paucity of treatment trials for dementia in Down syndrome in comparison to Alzheimer disease in the general (non-Down syndrome) population. This 2-year randomized, double-blind, placebo-controlled trial assessed […]
Quality of life and the effect of memantine in dementia with lewy bodies and Parkinson’s disease dementia
Larsson, Victoria,
Engedal, Knut,
Aarsland, Dag,
Wattmo, Carina,
Minthon, Lennart,
Londos, Elisabet
Aim: To investigate quality of life (QOL) and the effect of memantine treatment in patients with Lewy body dementias.; Methods: A secondary analysis of a randomized controlled study in 70 patients with Parkinson’s disease dementia (PDD) or dementia with Lewy bodies (DLB) over 24 weeks using caregiver-rated QOL-Alzheimer’s disease (AD) in domains according to the […]
A randomized placebo controlled trial of homocysteine lowering to reduce cognitive decline in older demented people
Kwok, T.,
Lee, J.,
Law, C. B.,
Pan, P. C.,
Yung, C. Y.,
Choi, K. C.,
Lam, L. C.
Introduction: Whether homocysteine lowering by B vitamins can reduce cognitive decline in Alzheimer disease and vascular dementia patients is unclear.; Methods and Materials: 140 subjects with mild to moderate Alzheimer disease or vascular dementia were randomly assigned to take 1 mg of methylcobalamin and 5 mg of folic acid, or placebo once daily for 24 […]
Efficacy of a medical food on cognition in Alzheimer’s disease: results from secondary analyses of a randomized, controlled trial
Kamphuis, P. J. G. H.,
Verhey, F. R. J.,
Olde Rikkert, M. G. M.,
Twisk, J. W. R.,
Swinkels, S. H. N.,
Scheltens, P.
Objective: To investigate the extent that baseline cognitive impairment and intake adherence affected the 13-item Alzheimer’s Disease Assessment Scale – cognitive subscale (ADAS-cog) intervention response of a medical food in Alzheimer’s Disease (AD) patients. DESIGN/SETTING/PARTICIPANTS /INTERVENTION/MEASUREMENTS: This analysis was performed on data from a proof-of-concept study, consisting of a 12-week, double-blind, randomized, controlled, multicenter trial, […]